PALS: Color-Coded Length-Based Resuscitation Tape

Equipment	GRAY 3-5 kg	PINK Small Infant 6-7 kg	RED Infant 8-9 kg	PURPLE Toddler 10-11 kg	YELLOW Small Child 12-14 kg
Resuscitation bag		Infant/child	Infant/child	Child	Child
Oxygen mask (NRB)		Pediatric	Pediatric	Pediatric	Pediatric
Oral airway (mm)		50	50	60	60
Laryngoscope blade (size)		1 Straight	1 Straight	1 Straight	2 Straight
ET tube (mm)		3.5 Uncuffed 3.0 Cuffed	3.5 Uncuffed 3.0 Cuffed	4.0 Uncuffed 3.5 Cuffed	4.5 Uncuffed 4.0 Cuffed
ET tube insertion length (cm)	3 kg 9-9.5 4 kg 9.5-10 5 kg 10-10.5	10.5-11	10.5-11	11-12	13.5
Suction catheter (F)		8	8	10	10
BP cuff	Neonatal #5/ infant	Infant/child	Infant/child	Child	Child
IV catheter (ga)		22-24	22-24	20-24	18-22
IO (ga)		18/15	18/15	15	15
NG tube (F)		5-8	5-8	8-10	10
Urinary catheter (F)	5	8	8	8-10	10
Chest tube (F)		10-12	10-12	16-20	20-24

Equipment	WHITE Child 15-18 kg	BLUE Child 19-23 kg	ORANGE Large Child 24-29 kg	GREEN Adult 30-36 kg
Resuscitation bag	Child	Child	Child	Adult
Oxygen mask (NRB)	Pediatric	Pediatric	Pediatric	Pediatric/adult
Oral airway (mm)	60	70	80	80
Laryngoscope blade (size)	2 Straight	2 Straight or curved	2 Straight or curved	3 Straight or curved
ET tube (mm)	5.0 Uncuffed 4.5 Cuffed	5.5 Uncuffed 5.0 Cuffed	6.0 Cuffed	6.5 Cuffed
ET tube insertion length (cm)	14-15	16.5	17-18	18.5-19.5
Suction catheter (F)	10	10	10	10-12
BP cuff	Child	Child	Child	Small adult
IV catheter (ga)	18-22	18-20	18-20	16-20
IO (ga)	15	15	15	15
NG tube (F)	10	12-14	14-18	16-18
Urinary catheter (F)	10	10-12	12	12
Chest tube (F)	20-24	24-32	28-32	32-38

PALS: Respiratory Emergencies


FYI Medications to Avoid in Children w/ Neuromuscular


Disease

Recall that the use of succinylcholine for intubation of children w/ neuromuscular diseases may trigger life-threatening conditions, such as hyperkalemia or malignant hyperthermia. Several commonly used drugs, such as aminoglycosides, have intrinsic neuromuscular blocking activity that can worsen respiratory muscle weakness.

The Management of Respiratory Emergencies Flowchart summarizes general management of respiratory emergencies and specific management by etiology. Note that this chart does not include all respiratory emergencies; it provides key management strategies for a limited number of diseases.

Management of Respiratory Emergencies Flowchart · Airway positioning · Pulse oximetry Suction as needed · ECG monitor (as indicated) Oxygen · BLS as indicated **Specific Management for Selected Conditions Upper Airway Obstruction** Croup **Anaphylaxis Aspiration Foreign Body** · Nebulized epinephrine IM epinephrine (or autoinjector) · Allow position of comfort Corticosterioids Albuterol · Specialty consultation Antihistamines Corticosteroids **Lower Airway Obstruction RSV** Bronchiolitis Asthma see pg 188 for asthma ladder Nasal suctioning Albuterol ± ipratropium Magnesium sulfate Bronchodilator trial Corticosteroids Terbutaline re, consider palivizumab (mAB) or ribavirin for Subcutaneous epinephrine immunocompromised **Lung Tissue Disease Pulmonary Edema** Pneumonia/Pneumonitis Cardiogenic or Noncardiogenic (ARDS) **Infectious Chemical Aspiration** Consider noninvasive or invasive ventilatory support w/ Albuterol Antibiotics (as indicated) PEEP Consider vasoactive support Consider diuretic **Disordered Control of Breathing Increased ICP** Poisoning/Overdose **Neuromuscular Disease** Consider noninvasive or invasive Avoid hypoxemia Antidote (if available) ventilatory support Avoid hypercarbia · Contact poison control Avoid hyperthermia





PALS: Recognition and Management of Shock


	Recognition of Shock Flowchart						
Clinical Signs Hypovolemic Distributive Cardiogenic Obstruct							
A	Patency	Air	way open and maintaina	ble/not maintainable)		
	Respiratory Rate		Increase	ed			
В	Respiratory Effort	Normal to increased Labored					
	Breath Sounds	Normal	, grunting				
	Systolic Blood Pressure	Compensated Shock → Hypotensive Shock					
	Pulse Pressure	Narrow	Variable	Nai	rrow		
	Heart Rate	Increased					
С	Peripheral Pulse Weak Bounding or weak		Weak				
	Skin	Pale, cool	Pale, cool Warm or cool Pale		, cool		
	Capillary Refill	Delayed	Variable	Dela	ayed		
	Urine Output	Decreased					
D	Level of Consciousness	Irritable early Lethargic late					
Ε	Temperature	Variable					

Management of Shock Flowchart Oxygen • IV/IO access Pulse oximetry BLS as indicated • ECG monitor • Point-of-care glucose testing **Specific Management for Selected Conditions Hypovolemic Shock** Nonhemorrhagic Hemorrhagic • 20 mL/kg NS/LR bolus, repeat as needed • Control external bleeding • Consider colloid • 20 mL/kg NS/LR bolus, repeat 2 or 3x as needed • Transfuse PRBCs as indicated **Distributive Shock** Septic **Anaphylactic** Neurogenic Management Algorithm: • IM epinephrine (or autoinjector) • 20mL/kg NS/LR bolus, repeat Septic Shock • Fluid boluses (20mL/kg NS/LR) Vasopressor Albuterol • Antihistamines, corticosteroids • Epinephrine infusion

PALS: Recognition and Management of Shock

Management of Shock Flowchart				
	Cardioge	nic Shock		
Bradyarrhythmia/Tachyarrhythmia (e.g. CHD, Myocarditis, Cardiomyopathy, Poisoning)				
Management Algorithm: • Bradycardia • Tachycardia w/ poor perfus	sion	 5 to 10 mL/kg NS/LR bolus, repeat PRN Vasoactive infusion Consider expert consultation 		
	Obstructi	ive Shock		
Ductal-Dependent Tension (LV Outflow Obstruction) Pneumothorax		Cardiac Tamponade	Pulmonary Embolism	
 Prostaglandin E₁ Expert consultation 	Needle decompression Tube thoracostomy	Pericardiocentesis 20 mL/kg NS/LR bolus	20 mL/kg NS/LR bolus, repeat PRN Consider thrombolytics, anticoagulants Expert consultation	

	Shock					
Hemodynan	Hemodynamic Parameters in Shock					
Туре	Examples	Preload (CVP, PCWP)	Afterload (SVR)	CO (SV*HR)	Mixed venous O ₂	Treatment
Distributive	 Sepsis Anaphylaxis Severe neurologic injury (loss of α-1 activity) 	↓	1	↑ then ↓	1	Sepsis: crystalloid (20 cc/kg NS, repeat PRN) + abx Anaphylaxis: epi + crystalloid Neurogenic: crystalloid + α-active pressors, (norepi @ 0.05-2 mcg/kg/min)
Hypovolemic	Blood loss GI or Renal losses intake	decreased not increased!!	1	ecreased not increas	s <mark>dll</mark>	Crystalloid replacement: 20 cc/ kg, repeat PRN For blood loss: c/s PRBCs
Cardiogenic	Myocarditis MI Dysrhythmia	1	1	ecreased not increase	sd!! ↓	Targeted at etiology - inotropes, revascularization, anti-arrhythmics, cardiovert
Obstructive	Tamponade PE	↑	1	ecreased not increase	edi!	Fix obstruction (pericardiocentesis, thrombectomy/lysis for PE)



PALS: Cardiac Arrest

Doses/Details for the Pediatric Cardiac Arrest Algorithm

CPR Quality

- Push hard (≥½ of anteroposterior diameter of chest) and fast (100-120/min) and allow complete chest recoil.
- Minimize interruptions in compressions.
- Avoid excessive ventilation.
- Rotate compressor every 2 minutes, or sooner if fatigued.
- If no advanced airway,
 15:2 compression-ventilation ratio.

Shock Energy for Defibrillation

First shock 2 J/kg, second shock 4 J/kg, subsequent shocks ≥4 J/kg, maximum 10 J/kg or adult dose

Drug Therapy

- Epinephrine IO/IV dose:

 0.01 mg/kg (0.1 mL/kg of the
 0.1mg/mL concentration). Repeat every 3-5 minutes. If no IO/IV access, may give endotracheal dose: 0.1 mg/kg (0.1 mL/kg of the 1 mg/mL concentration).
- Amiodarone IO/IV dose:
 5 mg/kg bolus during cardiac arrest. May repeat up to 2 times for refractory VF/pulseless VT.
- Lidocaine IO/IV dose: Initial: 1 mg/kg loading dose. Maintenance: 20-50 mcg/kg per minute infusion (repeat bolus dose if infusion initiated >15 minutes after initial bolus therapy).

Advanced Airway

- Endotracheal intubation or supraglottic advanced airway
- Waveform capnography or capnometry to confirm and monitor ET tube placement
- Once advanced airway in place, give 1 breath every 6 seconds (10 breaths/min) with continuous chest compressions

Return of Spontaneous Circulation (ROSC)

- Pulse and blood pressure
- Spontaneous arterial pressure waves with intra-arterial monitoring

Reversible Causes

- Hypovolemia
- Hypoxia
- Hydrogen ion (acidosis)
- Hypoglycemia
- Hypo-/hyperkalemia
- Hypothermia
- Tension pneumothorax
- Tamponade, cardiac
- Toxins
- Thrombosis, pulmonary
- Thrombosis, coronary

Estimating Endotracheal Tube Size

The formula for estimation of proper endotracheal tube size (internal diameter [i.d.]) for children 2 to 10 years of age, based on the child's age:

Uncuffed endotracheal tube size (mm i.d.) = (age in years/4) + 4

The formula for estimation of a cuffed endotracheal tube size is as follows:

Cuffed endotracheal tube size (mm i.d.) = (age in years/4) + 3.5 Typical cuffed inflation pressure should be <20 to 25 cm H₂O.

Drugs Used in PALS

Drug	Indications/Dosages					
Adenosine	VT O.1 mg/kg IV/IO rapid push (max 6 mg), second dose 0.2 mg/kg IV/IO rapid push (max 12 mg)					
Albuterol	Asthma, anaphylaxis (bronchospasm), hyperkalemia MDI: 4 to 8 puffs via inhalation q 20 minutes PRN with spacer (or ET if intubated Nebulizer: 2.5 mg/dose (wt <20 kg) or 5 mg/dose (wt >20 kg) via inhalation q 20 minutes PRN Continuous nebulizer: 0.5 mg/kg per hour via inhalation (max 20 mg/h)					
Amiodarone	SVT, VT (with pulses) • 5 mg/kg IV/IO load over 20 to 60 minutes (max 300 mg), repeat to daily max 15 mg/kg (2.2 g in adolescents) Pulseless arrest (ie, VF/pulseless VT) • 5 mg/kg IV/IO bolus (max 300 mg), repeat to daily max 15 mg/kg (2.2 g in adolescents)					
Atropine sulfate	Bradycardia (symptomatic) 0.02 mg/kg IV/IO (max single dose 0.5 mg), may repeat dose once in 3 to 5 minutes max total dose child 1 mg, max total dose adolescent 3 mg 0.04 to 0.06 mg/kg ET Toxins/overdose (eg. organophosphate, carbamate) 12 years: 0.05 mg/kg IV/IO initially; then repeated and doubling the dose every 5 minutes until muscarinic symptoms reverse 212 years: 1 mg IV/IO initially; then repeated and doubling the dose every 5 minutes until muscarinic symptoms reverse					
Calcium chloride 10%	Hypocalcemia, hyperkalemia, hypermagnesemia, calcium channel blocker overdose • 20 mg/kg (0.2 mL/kg) IV/IO slow push during arrest, repeat PRN					
Calcium gluconate	Hypocalcemia, hyperkalemia, hypermagnesemia, calcium channel blocker overce • 60 mg/kg (0.6 mL/kg) IV/IO slow push during arrest; repeat PRN					
Dexamethasone	Croup • 0.6 mg/kg PO/IM/IV (max 16 mg)					
Dextrose (glucose)	Hypoglycemia • 0.5 to 1 g/kg IV/IO (D ₂₆ W 2 to 4 mL/kg; D ₁₀ W 5 to 10 mL/kg)					
Dobutamine	Heart failure, cardiogenic shock • 2 to 20 mcg/kg per minute IV/IO infusion; titrate to desired effect					
Dopamine	Cardiogenic shock, distributive shock • 2 to 20 mcg/kg per minute IV/IO infusion; titrate to desired effect					
Epinephrine	Pulseless arrest, bradycardia (symptomatic) • 0.01 mg/kg (0.1 mL/kg of the 0.1 mg/mL concentration) IV/IO q 3 to 5 minutes (max single dose 1 mg) • 0.1 mg/kg (0.1 mL/kg of the 1 mg/mL concentration) ET q 3 to 5 minutes Hypotensive shock • 0.1 to 1 mcg/kg per minute IV/IO infusion (consider higher doses if needed) Anaphylaxis • IM autoinjector 0.3 mg (for patient weighing ≥30 kg) or IM junior autoinjector 0.15 mg (for patient weighing 10 to 30 kg) • 0.01 mg/kg (0.01 mL/kg of the 1 mg/mL concentration) IM q 15 minutes PRN (max single dose 0.3 mg) • 0.01 mg/kg (0.1 mL/kg of the 0.1 mg/mL concentration) IV/IO q 3 to 5 minutes (max single dose 1 mg) if hypotensive • 0.1 to 1 mcg/kg per minute IV/IO infusion if hypotension persists despite fluids and IM injection Asthma • 0.01 mg/kg (0.01 mL/kg of the 1 mg/mL concentration) subcutaneously q 15 minutes (max 0.3 mg or 0.3 mL) Croup • 0.25 to 0.5 mL racemic solution (2.25%) mixed in 3 mL NS via inhalation • 3 mg (3 mL of the 1 mg/mL concentration) via inhalation					

Drugs Used in PALS

Drug	Indications/Dosages			
Etomidate	RSI rapid sequence intubation 0.2 to 0.4 mg/kg IV/IO infused over 30 to 60 seconds (max 20 mg) will produce rapid sedation that lasts for 10 to 15 minutes			
Hydrocortisone	Adrenal insufficiency 2 mg/kg IV bolus (max 100 mg)			
Ipratropium bromide	Asthma • 250 to 500 mcg via inhalation q 20 minutes PRN × 3 doses			
Lidocaine	VF/pulseless VT, wide-complex tachycardia (with pulses) 1 mg/kg IV/IO bolus Maintenance: 20 to 50 mcg/kg per minute IV/IO infusion (repeat bolus dose if infusion initiated >15 minutes after initial bolus) 2 to 3 mg/kg ET			
Magnesium sulfate	Asthma (refractory status asthmaticus), torsades de pointes, hypomagnesemia 25 to 50 mg/kg IV/IO bolus (max 2 g) (pulseless VT) or over 10 to 20 minutes (VT with pulses) or slow infusion over 15 to 30 minutes (status asthmaticus)			
Methyl- prednisolone	Asthma (status asthmaticus), anaphylactic shock • Load: 2 mg/kg IV/IO/IM (max 60 mg); only use acetate sait IM • Maintenance: 0.5 mg/kg IV/IO q 6 hours (max 120 mg/d)			
Milrinone	Myocardial dysfunction and increased SVR/PVR Loading dose: 50 mcg/kg IV/IO over 10 to 60 minutes followed by 0.25 to 0.75 mcg/kg per minute IV/IO infusion			
Naloxone	Narcotic (opiate) reversal Total reversal required (for narcotic toxicity secondary to overdose): 0.1 mg/kg IV/IO/IM/subcutaneous bolus q 2 minutes PRN (max 2 mg) Total reversal not required (eg, for respiratory depression associated with therap narcotic use): 1 to 5 mcg/kg IV/IO/IM/subcutaneously; titrate to desired effect Maintain reversal: 0.002 to 0.16 mg/kg per hour IV/IO infusion			
Nitroglycerin	Heart failure, cardiogenic shock Initiate at 0.25 to 0.5 mcg/kg per minute IV/IO infusion; titrate by 1 mcg/kg per minute q 15 to 20 minutes as tolerated. Typical dose range 1 to 5 mcg/kg per minute (max 10 mcg/kg per minute) In adolescents, start with 5 to 10 mcg per minute (not per kilogram per minute) and increase to max 200 mcg per minute			
Nitroprusside	Cardiogenic shock (ie, associated with high SVR), severe hypertension • 0.3 to 1 mcg/kg per minute initial dose; then titrate up to 8 mcg/kg per minute PRN			
Norepinephrine	Hypotensive (usually distributive) shock (ie, low SVR and fluid refractory) • 0.1 to 2 mcg/kg per minute IV/IO infusion; titrate to desired effect			
Procainamide	SVT, atrial flutter, VT (with pulses) 15 mg/kg IV/IO load over 30 to 60 minutes (do not use routinely with amiodarone)			
Prostaglandin E, (PGE,)	Ductal-dependent congenital heart disease (all forms) 0.05 to 0.1 mcg/kg per minute IV/IO infusion initially; then 0.01 to 0.05 mcg/kg per minute IV/IO Ductal-dependent congenital heart disease (all forms) 1. 0.05 to 0.1 mcg/kg per minute IV/IO Ductal-dependent congenital heart disease (all forms)			
Sodium bicarbonate	Metabolic acidosis (severe), hyperkalemia 1 mEq/kg IV/IO slow bolus Sodium channel blocker overdose (eg, tricyclic antidepressant) 1 to 2 mEq/kg IV/IO bolus until serum pH is >7.45 (7.50 to 7.55 for severe poisoning followed by IV/IO infusion of 150 mEq NaHCO ₃ /L solution titrated to maintain alkalosis			
Terbutaline	Asthma (status asthmaticus), hyperkalemia 0.1 to 10 mcg/kg per minute IV/IO infusion; consider 10 mcg/kg IV/IO load over 5 minutes 10 mcg/kg subcutaneously q 10 to 15 minutes until IV/IO infusion is initiated (max single dose 0.4 mg)			
Vasopressin	Catecholamine-resistant hypotension • 0.0002 to 0.002 unit/kg per minute (0.2 to 2 milliunits/kg per minute) continuous infusion			